Abstract
Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate Acalabrutinib or 4-{8-Amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1- yl}-N-(pyridin-2-yl)benzamide is the active pharmaceutical ingredient (API) in the form of the maleate salt monohydrate in CALQUENCE® tablets, a prescription medication for use in the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). A tablet dosage form of CALQUENCE® comprising Acalabrutinib maleate monohydrate has since been approved by the FDA on Aug 3, 2022.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Anonymous, "Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate", Technical Disclosure Commons, (October 07, 2024)
https://www.tdcommons.org/dpubs_series/7406